3
Clinical Trials associated with 68Ga-NTA-476Uptake, Safety and Tolerability of 68Ga-NTA-476 Imaging of Prostate Cancer Tumours
A Single-Arm Comparative Imaging study to evaluate the uptake of 68Ga-NTA-476 on PET/CT Compared to Standard of Care 18F-DCFPyL PET/CT in Men with Prostate Cancer
Start Date14 Aug 2024 |
Sponsor / Collaborator- |
A Single-Arm Comparative Imaging Study of 68Ga-NTA-476 PET/CT Compared to Standard of Care 18F-DCFPyL PET/CT in Men With Prostate Cancer
This study is investigating a new agent to be used in PET imaging for prostate cancer, called 68Ga-NTA-476. It aims to find out where 68Ga-NTA-476 goes in the body once it is injected into a person and whether there are any side effects or issues with tolerating the compound. This will be compared to an existing imaging compound which is currently used in Australia called 18F-DCFPyl. 68Ga-NTA-476 has been developed and tested in the laboratory; however, this is the first time that it will be tested in humans.
100 Clinical Results associated with 68Ga-NTA-476
100 Translational Medicine associated with 68Ga-NTA-476
100 Patents (Medical) associated with 68Ga-NTA-476
100 Deals associated with 68Ga-NTA-476